Dendreon (DNDN) Reports Mixed Q2 Results
More News related to DNDN
- Dendreon (DNDN) May volatility elevated at 99 into data
- Dendreon (DNDN) volatility of 65 near two-year lows
- Dendreon (DNDN) Completes Submission of Amended Biologics License Application for PROVENGE®
- Dendreon (DNDN) Completes Submission of Biologics License Application for PROVENGE
- Dendreon Completes Submission of Biologics License Application for PROVENGE
More News related to Earnings
- CAE (CAE) Posts Q2 EPS of CDN$0.15, Down Y/Y; Revs Miss Views
- Grubb & Ellis (GBE) Posts Q3 Loss of $0.33, Tops Y/Y; Revs Beat Estimates
- PHC (PHC) Posts Q1 EPS of 1c, Better Y/Y
- Atrinsic (ATRN) Posts Q3 Loss of $0.12, Tops Y/Y
- Macy's (M) Reports Better-Than-Expected Q3 Loss of $0.03; Raises Q4 Outlook Below the Street
Dendreon (Nasdaq: DNDN) reports Q2 loss of $0.18, 4 cents better than the analyst estimate of ($0.22). Revenues for the quarter were $26k, versus the consensus of $70k.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that harness the immune system to fight cancer.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
